They should also not be used by individuals who have had a serious allergic reaction to semaglutide
Clinical trials show Semaglutide can produce meaningful weight loss: on average about 15% of starting body weight after roughly 68 weeks of treatment
23, Novo Nordisk released late-stage study results showing participants who took its next-generation obesity drug, CagriSema, didn't lose as much weight as those who took rival Eli Lilly's Zepbound
Given the wide use of these drugs, these adverse events, although rare, must be considered by patients thinking about using them for weight loss, said first author Mohit Sodhi, a graduate of UBCs experimental medicine program and fourth-year UBC medical student studying the adverse events of commonly prescribed medications
What sits on the other side of that gap is decades of animal studies showing consistent effects across tissue repair, inflammation, neurological function, and metabolic health